Clinical Research Papers:
Young breast cancer patients who develop distant metastasis after surgery have better survival outcomes compared with elderly counterparts
PDF | HTML | How to cite
Metrics: PDF 1867 views | HTML 1876 views | ?
Jingjing Wang1, Jiayu Wang1, Qing Li1, Pin Zhang1, Peng Yuan1, Fei Ma1, Yang Luo1, Ruigang Cai1, Ying Fan1, Shanshan Chen1, Qiao Li1 and Binghe Xu1
1 Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Binghe Xu, email:
Keywords: breast cancer; young age; locoregional relapse; distant metastasis; prognosis
Received: November 09, 2016 Accepted: January 11, 2017 Published: July 04, 2017
To investigate the recurrence pattern and subsequent survival outcomes in young breast cancer population, 483 young patients (≤ 35) and 739 elderly patients (≥ 65), who received mastectomy or breast-conserving surgery from 2008 to 2012, were included in this study. The young population presented with a higher rate of pathologic tumor stage (P < 0.001), positive pathologic lymph node (P < 0.001), grade III tumors (P < 0.001), and lymphovascular invasion (P < 0.001). With a median follow-up of 56.5 months, young patients had a significantly lower 5-year disease-free survival (73.7% vs 83.4%, P = 0.001), while no difference in 5-year overall survival was observed (91.7% vs 91.7%, P = 0.721). The 5-year cumulative incidences of locoregional relapse (8.9% vs 4.3%, P = 0.009) and distant metastasis (18.8% vs 9.5%, P < 0.001) were significantly higher in the young population. However, for patients with distant metastasis, the survival outcomes were significantly better in the young patients (5-year overall survival since diagnosis: 60.0% vs 47.3%, P = 0.025; 5-year overall survival after recurrence: 31.0% vs 24.3%, P = 0.001). Young breast cancer patients present with more aggressive clinicopathological features and have poor prognosis compared with elderly. But young patients with distant metastasis might have better survival outcomes.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.